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lChBACKGROUND Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be
quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%).
Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis.
OBJECTIVES This study sought to determine associations between ECV% and markers of left ventricular
decompensation and post-intervention clinical outcomes.
METHODS Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified
Look-Locker inversion recovery–based T1 mapping and late gadolinium enhancement before aortic valve intervention. A
central core laboratory quantified CMR parameters.
RESULTS Four-hundred forty patients (age 70  10 years, 59% male) from 10 international centers underwent CMR a
median of 15 days (IQR: 4 to 58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer,
magnetic field strength, or T1 mapping sequence (all p > 0.20). ECV% correlated with markers of left ventricular
decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late
gadolinium enhancement, and lower left ventricular ejection fraction (p < 0.05 for all), the latter 2 associations being
independent of all other clinical variables (p ¼ 0.035 and p < 0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years)
of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mor-
tality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p ¼ 0.009).
Not only was ECV% associated with cardiovascular mortality (p ¼ 0.003), but it was also independently associated with
all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio
per percent increase in ECV%: 1.10; 95% confidence interval [1.02 to 1.19]; p ¼ 0.013).
CONCLUSIONS In patients with severe aortic stenosis scheduled for aortic valve intervention, an increased ECV%
is a measure of left ventricular decompensation and a powerful independent predictor of mortality. (J Am Coll Cardiol
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resonance
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ECV% = extracellular volume
fraction
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305A ortic stenosis is a disease of both the valveand myocardium. Progressive myocardialremodeling and hypertrophy occur over
time in response to sustained pressure overload,
decreasing wall stress, and maintaining cardiac per-
formance. However, if untreated, this hypertrophic
response eventually decompensates, and patients
transition to symptomatic heart failure and adverse
events (1).SEE PAGE 317 iECV = indexed extracellular
volume
LA = left atrial
LV = left ventricular
NYHA = New York Heart
Association
STS-PROM = Society of
Thoracic Surgeons Predicted
of MortalityMyocardial fibrosis is a key pathological process
driving left ventricular (LV) decompensation (2). Two
distinct patterns of fibrosis are observed: focal
replacement fibrosis and diffuse interstitial fibrosis
(3). Both forms of fibrosis can be detected non-
invasively using cardiovascular magnetic resonance
(CMR): replacement fibrosis with the late gadolinium
enhancement technique and diffuse interstitial
fibrosis with newer T1 mapping approaches. Although
replacement fibrosis appears irreversible, regression
of diffuse fibrosis is observed following relief of
pressure overload with aortic valve intervention
(4–6). Robust assessment of diffuse fibrosis is there-
fore desirable to identify early LV decompensation at
a stage when pathological myocardial changes are
largely reversible and targeted early valve interven-
tion may improve patient outcomes.
Several T1 mapping measures have been proposed
to date to detect changes in diffuse myocardial
fibrosis. Native T1 mapping produces a voxel-based
map of the myocardium that estimates absolute
myocardial T1 values (7). Extracellular volume (ECV)-
based measures utilize extracellular gadolinium-
based contrast agents to calculate the relative
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the myocardium (8,9). Although each mea-
sure has been validated against histology
(8–16), the optimal T1 mapping approach re-
mains unclear and robust multicenter
outcome data are lacking.
In the present study, we investigated CMR
T1 mapping in a large international multi-
center study of patients with severe aortic
stenosis scheduled for aortic valve interven-
tion. In particular, we investigated the asso-
ciation between ECV-based measures and
clinical characteristics, markers of LV
decompensation and post-intervention clin-
ical outcomes.
METHODSPATIENT POPULATIONS. Patients with American
Heart Association/American College of Cardiology/
European Society of Cardiology criteria (17,18) for
severe aortic stenosis who were awaiting aortic valve
intervention were recruited as part of multiple pro-
spective observational cohorts from 10 centers across
Europe, North America, and Asia: the United
Kingdom (The British Society of Cardiovascular
Magnetic Resonance Consortium: Edinburgh, Leeds,
Leicester, London [Barts Heart Centre], and Oxford),
Germany (Berlin), United States (Pittsburgh), Canada
(Québec), and South Korea (Seoul) (Online Table 1).
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FIGURE 1 Flow Diagram of Study Participants
Total original cohort
n = 462
CMR analysis
n = 453
EXCLUDED:
• Missing hematocrit n = 9
EXCLUDED:
• Amyloidosis n = 3
• Anderson-Fabry disease n = 1
• Myocarditis n = 1
• Unable to analyze T1 maps n = 8
LOST TO FOLLOW UP:
• n = 0
Included post-CMR analysis
n = 440
DATA AVAILABLE FOR
PRIMARY OUTCOME
n = 440
SAVR
N = 373
TAVR
N = 67
Primary outcome
(median 3.8 [2.8, 4.6] years follow-up)
Aortic valve intervention
(median 15 [4, 58] days post-CMR)
CMR ¼ cardiovascular magnetic resonance; SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter aortic valve replacement.
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306replacement, and presence of another coexistent
myocardial pathology such as cardiac amyloidosis,
hypertrophic cardiomyopathy, or myocarditis. The
study was conducted according to the Declaration
of Helsinki and approved by the relevant local
research ethics committees. Written informed con-
sent was obtained from all participants. All patients
underwent comprehensive medical history and
physical examination. Transthoracic echocardiogra-
phy was performed according to international
clinical guidelines and within accredited tertiary
echocardiographic units. Particular focus was
placed upon measurement of aortic stenosis
severity, which was assessed on the basis of the
peak velocity, mean gradient, and aortic valve
area (17–19).
CARDIOVASCULAR MAGNETIC RESONANCE. CMR
was performed on a range of different scanners, T1
mapping pulse sequences, and field strengths (Online
Table 1). Standard long-axis cine images were ac-
quired as well as a short-axis cine stack of the left
ventricle. Late gadolinium enhancement imagingwith both a short-axis LV stack and standard long-
axis views was performed 5 to 15 min following
gadolinium contrast agent administration. T1 map-
ping data were acquired in a short-axis mid-
ventricular view of the left ventricle both before and
10 to 20 min following gadolinium contrast
agent administration.
IMAGE POST-PROCESSING AND ANALYSIS. CMR
image analysis was performed by 2 operators (R.J.E.,
T.A.T.) within a core lab according to a standardized
analysis protocol (Online Appendix) using cvi42
software (Circle Cardiovascular Imaging, Calgary,
Canada). The operators were blinded to the outcome
data. Patients with CMR features consistent with a
diagnosis of an alternative myocardial pathology
were excluded (n ¼ 5). The short-axis stack was con-
toured to calculate left and right ventricular volumes,
ejection fraction, and LV mass, which were indexed
to body surface area (calculated using the Mosteller
formula). LV trabeculations and papillary muscles
were included in the myocardial mass and excluded
from the cavity volumes as per Society for
TABLE 1 Baseline Characteristics and Imaging Results by ECV% Tertile
ECV%
Tertile 1: <25.9%
(n ¼ 147)
Tertile 2: 25.9%–29.1%
(n ¼ 146)
Tertile 3: >29.1%
(n ¼ 147) p Value*
Age, yrs 68  9 70  10 71  11 0.07
Male 84 (57) 89 (61) 86 (59) 0.80
Body mass index, kg/m2 27.9  5.0 27.8  5.5 27.1  4.6 0.41
Body surface area, m2 1.86  0.25 1.85  0.23 1.84  0.24 0.69
Past medical history
Hypertension 90 (61) 93 (64) 97 (67) 0.60
Diabetes mellitus 25 (17) 29 (20) 39 (27) 0.11
Atrial fibrillation 15 (10) 15 (10) 26 (18) 0.09
Previous myocardial infarction 4 (3) 13 (10) 21 (16) 0.002
Coronary artery disease† 45 (12) 51 (35) 72 (49) 0.003
Clinical factors
NYHA functional class III or IV 35 (27) 54 (43) 68 (55) <0.001
Systolic blood pressure, mm Hg 131  18 133  22 128  19 0.17
Diastolic blood pressure, mm Hg 73  12 72  11 73  13 0.87
STS-PROM score, % 1.44 (0.88–2.29) 1.40 (0.92–2.15) 1.89 (1.13–3.31) <0.001
EuroSCORE II, % 1.24 (0.82–2.19) 1.44 (0.99–2.21) 2.18 (1.14–4.28) <0.001
Echocardiographic measures
Peak aortic-jet velocity, m/s 4.48  0.66 4.54  0.80 4.35  0.91 0.11
Peak aortic valve gradient, mm Hg 82  24 85  31 79  33 0.20
Mean aortic valve gradient, mm Hg 50  16 51  19 48  21 0.33
Aortic valve area, cm2 0.73  0.19 0.76  0.30 0.71  0.25 0.20
Indexed aortic valve area, cm2/m2 0.40  0.11 0.41  0.15 0.39  0.13 0.49
Valvuloarterial impedance, mm Hg/ml/m2 3.91  1.17 3.85  1.17 4.00  1.02 0.52
Bicuspid aortic valve 47 (34) 47 (35) 50 (37) 0.87
Discordant echocardiographic measures of severity 25 (17) 25 (17) 33 (22) 0.40
Low-flow, low-gradient subtype (preserved or reduced ejection fraction) 7 (5) 6 (4) 13 (9) 0.16
Cardiovascular magnetic resonance
Indexed left ventricular end-diastolic volume, ml/m2 70  22 80  29 85  31 <0.001
Indexed left ventricular end-systolic volume, ml/m2 17 (11–28) 21 (14–36) 30 (17–51) <0.001
Indexed left ventricular stroke volume, ml/m2 49  12 51  15 47  13 0.032
Left ventricular ejection fraction, % 72  13 67  15 59  18 <0.001
Left ventricular ejection fraction <50% 10 (7) 22 (15) 39 (27) <0.001
Left ventricular mass index, g/m2 86  28 94  32 100  35 0.001
Maximum left ventricular wall thickness, mm 15  3 15  3 15  3 0.45
Mass/volume, g/ml 1.27  0.35 1.25  0.46 1.23  0.36 0.68
Indexed right ventricular end-diastolic volume 64  18 64  16 67  20 0.22
Indexed right ventricular end-systolic volume, ml/m2 21 (16–27) 21 (15–29) 23 (16–30) 0.18
Indexed right ventricular stroke volume, ml/m2 41  11 42  11 41  10 0.77
Right ventricular ejection fraction, % 65  9 65  10 62  13 0.03
Indexed left atrial volume, ml/m2 48  21 54  22 58  25 <0.001
Late gadolinium enhancement 55 (37) 73 (50) 92 (63) <0.001
Late gadolinium enhancement as a percentage of myocardial mass
(full-width-at-half-maximum method), %
2.94 (1.61–4.26) 3.77 (1.89–7.48) 5.10 (2.36–7.93) 0.067
Late gadolinium enhancement (mid-wall pattern)
present in segment 9
4 (3) 4 (3) 8 (5) 0.36
Hematocrit, % 0.41  0.04 0.39  0.04 0.38  0.05 <0.001
Lambda 0.41  0.04 0.45  0.03 0.51  0.05 <0.001
ECV%, % 23.9  1.6 27.4  1.0 31.7  2.4 -
iECV, ml/m2 18.5 (15.3–22.4) 22.9 (18.9–28.9) 28.3 (22.4–35.1) <0.001
Clinical events
All-cause mortality, rate/1,000 patient-yrs 17.3 31.6 52.7 0.009
Cardiovascular mortality, rate/1,000 patient-yrs 4.0 5.7 18.6 0.047
Values are mean  SD, n (%), or median (interquartile range), unless otherwise indicated. The p values in bold are statistically significant. *The p values refer to tests for trends. †Coronary
artery disease defined as history of previous myocardial infarction, obstructive disease on angiography (stenosis >50% left main stem or >70% proximal epicardial coronary, artery) or
previous coronary intervention.
ECV% ¼ extracellular volume fraction; iECV ¼ indexed extracellular volume; NYHA ¼ New York Heart Association; STS-PROM ¼ Society of Thoracic Surgeons Predicted Risk of Mortality.
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FIGURE 2 Multiparametric CMR Assessment
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Cardiovascular magnetic resonance (CMR) short-axis cine images were contoured to provide ventricular volumes, mass, and ejection fraction (A). Areas of late
gadolinium enhancement (B, red arrows) were quantified using the full-width-at-half-maximum technique. Native (C) and post-contrast (D) T1 maps were analyzed,
and the mean value from segment 9 (shaded blue) and blood pool (orange contour) were used to calculate the extracellular volume fraction (ECV%). ECV% values did
not vary by field strength (p ¼ 0.98) (F), and minimal variation in ECV% values was observed across the different centers (G). By contrast, native T1 values varied
significantly by center (H), mainly due to the effect of magnetic field strength (blue ¼ 1.5-T, red ¼ 3.0-T). Contour legend: red ¼ left ventricular endocardial;
green ¼ left ventricular epicardial; yellow ¼ right ventricular endocardial; purple ¼ papillary muscle; orange ¼ blood pool region of interest; blue ¼ myocardial
(segment 9) region of interest. AMC ¼ Asan Medical Center, Seoul, Korea; BER ¼ Berlin, Germany; BHC ¼ Barts Heart Centre, London, United Kingdom;
EDI ¼ Edinburgh, United Kingdom; GLE ¼ Leicester, United Kingdom; LGI ¼ Leeds, United Kingdom; ORH ¼ Oxford, United Kingdom; QUE ¼ Québec, Canada;
Sh ¼ ShMOLLI T1 mapping sequence used; SNUH ¼ Seoul National University Hospital, Seoul, Korea; UPMC ¼ Pittsburgh, Pennsylvania.
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FIGURE 3 Markers of LV Decompensation Across ECV% and iECV Tertiles
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When comparing clinical and imaging variables across extracellular volume fraction (ECV%) tertiles, there was a progressive increase in LV mass (A), LV
end-diastolic volume (C), and proportion of patients with late gadolinium enhancement (E), with a reduction in LVEF (G). A similar pattern was seen when
comparing these characteristics across tertiles of indexed extracellular volume (iECV) (B, D, F, and H). EDVi ¼ indexed end-diastolic volume; LGE ¼ late
gadolinium enhancement; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction.
J A C C V O L . 7 5 , N O . 3 , 2 0 2 0 Everett et al.
J A N U A R Y 2 8 , 2 0 2 0 : 3 0 4 – 1 6 ECV440 Aortic Stenosis T1 Mapping
309
Everett et al. J A C C V O L . 7 5 , N O . 3 , 2 0 2 0
ECV440 Aortic Stenosis T1 Mapping J A N U A R Y 2 8 , 2 0 2 0 : 3 0 4 – 1 6
310Cardiovascular Magnetic Resonance recommenda-
tions (20). Left atrial (LA) volume was calculated via
the biplane area–length method and indexed to body
surface area (21).
The presence of noninfarct (mid-wall) and infarct
patterns of late gadolinium enhancement were
recorded and quantitative analysis performed using
the full-width-at-half-maximum technique (20),
with the extent of late gadolinium enhancement
expressed as a percentage of total LV mass. Areas of
signal contamination by epicardial fat or blood pool
were manually excluded. Patients with clear imag-
ing features of alternative myocardial pathology
(e.g., amyloidosis) were excluded from further
analysis.
Core lab T1 mapping analysis was performed using
a standardized pre-specified analysis protocol.
Epicardial and endocardial contours were manually
drawn in the midinferoseptum (segment 9 of the
standard 17-segment model [22]) on scanner-
generated, short-axis, native and post-contrast T1
maps at the mid-ventricular level. A 10% offset was
applied to minimize the influence of signal from the
adjacent blood pool and epicardial fat. A septal
segment was chosen because improved reproduc-
ibility has previously been demonstrated using septal
regions of interest compared with analysis of all mid-
ventricular segments on short-axis images (23). Seg-
ments containing noninfarct late gadolinium
enhancement were included in the T1 mapping anal-
ysis, whereas those with infarct late gadolinium
enhancement were excluded according to Society for
Cardiovascular Magnetic Resonance guidelines (24).
Native T1, ECV%, and iECV were then calculated
(Online Appendix). Interobserver reproducibility of
each of the T1 mapping measures was determined
from independent analysis of 15 randomly selected
scans. ECV% and iECV were pre-specified as the pre-
dominant T1 mapping measures for comparison
because of the potential advantages these measures
offer when comparing values acquired at different
magnetic field strengths (25) and with different
modified Look-Locker inversion recovery–based T1
mapping sequences (10).
LONGITUDINAL FOLLOW-UP AND CLINICAL EVENTS.
The primary outcome measure was all-cause mortal-
ity. The secondary outcome measure was cardiovas-
cular mortality, which was defined as death
attributable to myocardial ischemia or infarction,
heart failure, cardiac arrest (due to arrhythmia or
unknown cause), or cerebrovascular accident.
Outcome events were adjudicated by review ofpatient health records (including the U.K. Spine
database), and cause of death was adjudicated by 3
observers (P.B., J.P.G., M.R.D.). Among the centers in
the United Kingdom, death certificates were available
in all patients. Deaths occurring at international sites
outside of the United Kingdom were adjudicated us-
ing a combination of medical record review, reports
from family members, and death certificates
where available.
STATISTICAL ANALYSIS. The distribution of all
continuous variables was assessed using the Shapiro-
Wilk test and presented using mean  SD or median
(interquartile range). Comparisons between groups
were performed using the independent 2-sample
Student’s t-test or Mann-Whitney U test as appro-
priate. We presented all categorical variables as
counts and percentages and used the Fisher exact test
or chi-square test for comparison. The relationship
between 2 continuous variables was assessed using
Pearson’s r and Spearman’s rho as appropriate.
Comparisons between ECV% and iECV tertiles were
performed with 1-way analysis of variance or Kruskal-
Wallis test as appropriate.
The influence of imaging center, CMR scanner
manufacturer, magnetic field strength, and pulse
sequence on T1 mapping values was analyzed using
independent 2-sample Student’s t-tests and linear
regression analysis. Interobserver variability for
native T1 and ECV% was determined by calculating
the intraclass correlation coefficient on a random
sample of 15 scans. Univariable linear regression was
also performed to determine associations between
clinical and imaging variables with T1 mapping mea-
sures. Multivariable linear regression was then per-
formed using variables significantly associated with
T1 measures as well as important variables (e.g., age
and sex) regardless of strength of univariable associ-
ation. Univariable Cox-regression analysis was per-
formed to determine which variables were associated
with all-cause mortality as the primary outcome
measure as well as with cardiovascular mortality.
Time to event or final status check was taken from the
date of valve intervention. For all-cause mortality,
variables with a significant association were included
in the multivariable Cox regression model. The haz-
ard ratio (HR) per unit increase in the variable of in-
terest and 95% confidence intervals (CIs) were
expressed as HR (95% CI). All statistical analyses were
performed using SPSS version 24 (SPSS, IBM, Chicago,
Illinois) and GraphPad Prism version 8.0 (GraphPad
Software, San Diego, California). A 2-sided p < 0.05
was considered statistically significant.
FIGURE 4 Distribution of ECV% and Relationship With Clinical Events
LGE
LVEF <50%
Male sex
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311RESULTS
A total of 440 patients across 10 sites in 5 countries
were included in the final analysis (70  10 years, 59%
male) (Figure 1) with a large proportion having hy-
pertension (64%), diabetes mellitus (21%), and coro-
nary heart disease (38%) (Table 1 and Online Table 2).
Overall, 277 (63%) patients were imaged on 1.5-T and
163 (37%) patients on 3-T magnetic resonance scan-
ners. Aortic valve intervention was performed at a
median of 15 (IQR: 4 to 58) days following CMR. This
was either isolated surgical aortic valve replacement
(n ¼ 311, 71%), combined coronary artery bypass
grafting with surgical aortic valve replacement
(n ¼ 62, 14%), or transcatheter aortic valve replace-
ment (n ¼ 67, 15%).
NATIVE T1 VALUES. In keeping with previous work
(25,26), substantial variation in native T1 values was
observed between the different centers (Figure 2). In
particular, native T1 values were 20% higher in pa-
tients imaged at 3.0-T compared with 1.5-T (1,213 
57 ms vs. 1,042  50 ms; p < 0.001). In an exploratory
analysis, we adjusted native T1 values for local, sex-
specific normal T1 values acquired on the same
scanner using multiple methods (Online Methods,
Online Table 3). Although these adjusted native T1
measurements correlated with markers of LV
decompensation, they did not demonstrate an asso-
ciation with clinical outcomes (Online Results, Online
Tables 4 to 7).
ECV-BASED ASSESSMENTS (ECV% AND iECV).
ECV% values were consistent across the different
centers (Figure 2), with no differences between ECV%
values in patients imaged at 1.5-T and 3.0-T (27.7 
3.7% vs. 27.7  3.5%; p ¼ 0.975). On univariable linear
regression analysis, there was no association between
ECV% values and either magnetic field strength
(p ¼ 0.975), scanner manufacturer (p ¼ 0.416), or the
T1 mapping sequence used (p ¼ 0.246).
The mean ECV% was 27.7  3.6%, with good
interobserver variability (4.4  3.4%, intraclass cor-
relation coefficient ¼ 0.961). To explore associations
between ECV% and clinical variables, the total cohort
was divided into tertiles (tertile 1, <25.9%; tertile 2,
25.9 to 29.1%; tertile 3, >29.1%) (Table 1). Across the
tertiles, there was a progressive increase in patients
with established coronary heart disease (p ¼ 0.003),
Society of Thoracic Surgeons Predicted Risk of Mor-
tality (STS-PROM), and EuroSCORE II risk scores (both
p < 0.001). There was also progressive evidence of LV
decompensation with more patients classified as New
York Heart Association (NYHA) functional status III or
IV (p < 0.001), more patients demonstrating late
TABLE 2 Univariable Cox Regression Analysis for All-Cause Mortality
Univariable Analysis
Hazard Ratio (95% CI) p Value
Age, yrs 1.09 (1.05–1.13) <0.001
Male 2.45 (1.29–4.68) 0.006
STS-PROM score, % 1.37 (1.22–1.54) <0.001
EuroSCORE II, % 1.15 (1.10–1.21) <0.001
Known coronary disease 2.32 (1.34–4.00) 0.003
NYHA functional class III or IV 3.03 (1.63–5.61) <0.001
Atrial fibrillation 3.41 (1.87–6.22) <0.001
Peak aortic-jet velocity, m/s 0.68 (0.48–0.96) 0.030
Mean aortic valve gradient, mm Hg 0.98 (0.96–0.99) 0.009
Indexed aortic valve area, cm2/m2 0.76 (0.09–6.20) 0.80
Bicuspid aortic valve 0.57 (0.30–1.09) 0.088
LV ejection fraction <50% 1.85 (1.00–3.42) 0.049
Indexed LV end-diastolic volume, ml/m2 1.00 (1.00–1.01) 0.60
Indexed LV stroke volume, ml/m2 0.98 (0.95–1.00) 0.035
Indexed LV mass, g/m2 1.00 (0.99–1.01) 0.86
Indexed left atrial volume, ml/m2 1.02 (1.01–1.03) <0.001
Valvuloarterial impedance 1.20 (0.96–1.49) 0.11
Presence of late gadolinium enhancement 1.84 (1.05–3.23) 0.035
Late gadolinium enhancement as a
percentage of myocardial mass
(full-width-at-half-maximum method), %
1.01 (1.00–1.02) 0.009
Right ventricular ejection fraction, % 0.97 (0.95–1.00) 0.031
Hematocrit, % 0.95 (0.90–1.01) 0.073
Lambda 1.06 (1.02–1.11) 0.006
ECV%, % 1.15 (1.07–1.23) <0.001
iECV, ml/m2 1.02 (1.00–1.04) 0.120
The p values in bold are statistically significant.
CI ¼ confidence interval; ECV ¼ extracellular volume; LV ¼ left ventricular; other abbreviations as in Table 1.
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312gadolinium enhancement (p < 0.001) and a progres-
sive increase in indexed LA volumes, indexed LV
volumes, and LV mass index across the tertiles (all
p # 0.001) (Table 1, Figure 3). Moreover, there was a
fall in both left and right ventricular ejection fractions
across the tertiles, albeit largely within the normal
range (both p < 0.05) (Table 1). These analysis of
variance associations remained present on the uni-
variable analysis (Online Table 8), but on multivari-
able analysis, only increasing age (p ¼ 0.028), LV
ejection fraction (p < 0.001), and late gadolinium
enhancement (p ¼ 0.035) remained independently
associated with ECV%.
Median iECV was 22.5 (18.1 to 29.6) ml/m2. Analysis
by iECV tertile (tertile 1, <19.5 ml/m2; tertile 2, 19.5 to
26.9 ml/m2; tertile 3, >26.9 ml/m2) (Online Table 9)
demonstrated a progressive increase in the propor-
tion of males, subjects with coronary heart disease,
and surgical risk scores (EuroSCORE II; p < 0.01 for
all). Similar to ECV%, imaging markers of LV decom-
pensation (LV mass, LV volumes, LA volumes, late
gadolinium enhancement, and deterioration in LV
and right ventricular ejection fractions) alsoprogressed across the tertiles (Figure 3). Associations
with iECV on univariable analysis were similar to the
tertiles analysis (Online Table 10). On multivariable
analysis, clinical measures independently associated
with iECV were age, male sex, coronary heart disease,
peak aortic-jet velocity, indexed LA volume, late
gadolinium enhancement, and LV ejection fraction
(p < 0.05 for all).
CLINICAL OUTCOMES. Clinical outcome data were
collected from 440 patients after a median of 3.8
(IQR: 2.8 to 4.6) years. Final status checks were per-
formed between January and August 2018, and no
patient was lost to follow-up. Over this time, 52
deaths were observed (12%), of which 7 occurred
within 30 days of valve intervention (1 perioperative
death). Robust cause of death data was available in 37
of these events (71%), of which 14 (38%) were classi-
fied as a cardiovascular death following adjudication.
All-cause mortality progressively increased across
the ECV% tertiles, being approximately 3 times higher
in the top versus the bottom tertile (tertile 1, 17.3
deaths; tertile 2, 31.6 deaths; tertile 3, 52.7 deaths per
1,000 patient-years; log-rank test p ¼ 0.009)
(Figure 4). This relationship appeared numerically
consistent across intervention subgroups (Online
Table 11) although the absolute number of events in
these subgroups was small. Univariable Cox regres-
sion analysis showed a positive association between
ECV% and mortality (HR: 1.15; 95% CI: 1.07 to 1.23;
p < 0.001); other univariate predictors included age,
male sex, STS-PROM score, EuroSCORE II, atrial
fibrillation, indexed LA volume, coronary heart dis-
ease, and late gadolinium enhancement (all p < 0.05)
(Table 2). ECV% was also associated with confirmed
cardiovascular death on univariable analysis (HR:
1.22; 95% CI: 1.07 to 1.38; p ¼ 0.003), as was late
gadolinium enhancement (p ¼ 0.012) (Online
Table 12). ECV% remained associated with cardio-
vascular death when events that could not be classi-
fied due to insufficient information were also
included in this endpoint (HR: 1.15; 95% CI: 1.05 to
1.26; p ¼ 0.003).
Inclusion of variables in the multivariable models
was limited to prevent overfitting. In the first model,
ECV% remained predictive of the primary outcome
independent of age and sex (p ¼ 0.003) (Table 3). In
the second model, ECV% remained predictive inde-
pendent of age, sex, LV ejection fraction <50%, and
late gadolinium enhancement (HR: 1.10; 95% CI: 1.02
to 1.19; p ¼ 0.013) (Figure 4). This association
remained when peak aortic-jet velocity was added to
model 2 (model 3: p ¼ 0.033). Finally, ECV% was
associated with outcome independent of STS-PROM
TABLE 3 Multivariable Cox Regression Analysis of Association Between ECV%
and All-Cause Mortality
ECV%
95% CI for HR
p Value HR Lower Upper
All-cause mortality
Univariable
Model 1
ECV% <0.001 1.145 1.068 1.228
ECV% 0.003 1.124 1.047 1.207
Age, yrs <0.001 1.086 1.049 1.125
Male 0.001 2.921 1.520 5.614
Model 2
ECV% 0.013 1.100 1.020 1.186
Age, yrs <0.001 1.093 1.054 1.133
Male 0.004 2.649 1.363 5.148
LVEF <50% 0.213 1.535 0.782 3.012
Late gadolinium enhancement 0.329 1.351 0.738 2.475
Model 3
ECV% 0.033 1.088 1.007 1.176
Age, yrs <0.001 1.094 1.054 1.135
Male 0.005 2.591 1.325 5.067
LVEF <50% 0.233 1.527 0.761 3.064
Late gadolinium enhancement 0.508 1.233 0.663 2.293
Peak aortic-jet velocity, m/s 0.213 0.788 0.541 1.147
Model 4
ECV% 0.027 1.087 1.009 1.171
STS-PROM score, % <0.001 1.280 1.125 1.457
Model 5
ECV% 0.042 1.091 1.003 1.187
Known coronary disease 0.028 1.965 1.077 3.585
NYHA functional class III/IV 0.024 2.102 1.103 4.007
Atrial fibrillation 0.013 2.602 1.223 5.538
LV mass index 0.313 0.994 0.983 1.006
LA volume index 0.204 1.007 0.996 1.018
Cardiovascular mortality
Univariable
ECV% 0.003 1.215 1.068 1.382
Late gadolinium enhancement incorporates both infarct and noninfarct patterns. p Values in bold are statistically
significant.
HR ¼ hazard ratio; LA ¼ left atrial; LVEF ¼ left ventricular ejection fraction; other abbreviations as in Tables 1
and 2.
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313risk score in the fourth model (HR: 1.09; 95% CI: 1.01
to 1.17; p ¼ 0.027) and presence of coronary disease,
advanced NYHA functional status, presence of atrial
fibrillation, LV mass index, and LA volume index in
the fifth model (HR: 1.09; CI: 1.00 to 1.19; p ¼ 0.042).
There was no difference between all-cause mor-
tality rates when the cohort was analyzed by iECV
tertile (p ¼ 0.72) (Online Table 9) nor was iECV asso-
ciated with all-cause mortality or cardiovascular
death using univariable Cox regression analysis
(p ¼ 0.12 and p ¼ 0.32, respectively).
DISCUSSION
In patients with severe aortic stenosis undergoing
aortic valve replacement, diffuse myocardial fibrosis
quantified by CMR T1 mapping is an independent
predictor of all-cause mortality (Central Illustration).
These data show that both the percentage (ECV%) and
total volume (iECV) of diffuse fibrosis associate with
clinical and imaging measures of LV decompensation.
ECV% provides the most powerful independent
prognostic information, outperforming conventional
markers including late gadolinium enhancement and
ejection fraction, with a 1% rise in ECV% resulting in a
10% increase in mortality hazard. ECV-based T1
mapping indices, therefore, hold major promise as
fully quantitative markers of myocardial fibrosis and
LV decompensation in aortic stenosis.
The 2 ECV-based measures examined in this study
provide complementary information regarding
diffuse myocardial fibrosis. ECV% provides a surro-
gate marker of the percentage of myocardium made
up by fibrosis and has been validated extensively
against histological fibrosis (8,10–12). Whereas ECV%
offers a point assessment of fibrosis, serial ECV%
measurements are insensitive to changes in fibrosis
content, if fibrosis and cell volumes alter in propor-
tion (6). By contrast, the iECV (ECV%  indexed LV
myocardial volume) provides a surrogate measure of
the absolute fibrosis burden (9) that can better track
changes in fibrosis over time and in response to
intervention such as valve replacement (6). In our
cohort, both greater ECV% and iECV were associated
with multiple features of a decompensating ventricle:
advanced NYHA functional class and higher surgical
risk scores, as well as higher LV volumes, LA volumes,
presence and amount of late gadolinium enhance-
ment, and worsening LV ejection fraction. Our data,
therefore, support the utility of both ECV% and iECV
as objective markers of LV decompensation in aortic
stenosis. The lack of association of iECV with clinical
outcomes likely reflects the study population, which
also included a small proportion with discordantimaging measures, low-flow phenotypes, and a sub-
stantial female cohort who would be expected to have
lower LV mass (driving a lower iECV measurement),
but worse prognosis (27–29).
In aortic stenosis, prognostic T1 mapping data
have been limited to single-center studies (9,30).
This international multicenter investigation is the
largest study to date to our knowledge, and the first
to show a strong association between ECV% and
all-cause mortality in patients with aortic stenosis on
both univariable and multivariable models. After
correction for a variety of other well-established
prognostic markers, for every 1% increase in ECV%,
there was a 10% increase in risk of all-cause
CENTRAL ILLUSTRATION T1 Mapping Assessments of Myocardial Fibrosis in Aortic Stenosis
Everett, R.J. et al. J Am Coll Cardiol. 2020;75(3):304–16.
Extracellular volume fraction (ECV%) using cardiovascular magnetic resonance (CMR) serves as an objective marker of left ventricular
decompensation and is independently associated with long-term clinical outcomes in patients with aortic stenosis.
Everett et al. J A C C V O L . 7 5 , N O . 3 , 2 0 2 0
ECV440 Aortic Stenosis T1 Mapping J A N U A R Y 2 8 , 2 0 2 0 : 3 0 4 – 1 6
314mortality. These data are consistent with multiple
previous studies demonstrating the prognostic utility
in aortic stenosis of the other CMR marker of
myocardial fibrosis, late gadolinium enhancement
(9,28–31). Whereas late gadolinium enhancement
was again associated with an adverse prognosis in
this cohort, this association was lost when multi-
variable models including ECV% were performed,
suggesting ECV% measurement overlaps with some
of the adverse signal seen with late gadolinium
enhancement but also provides incremental prog-
nostic information. At biopsy, even small areas of
late gadolinium enhancement have been associated
with thousands of microscars, which could be the
primary driver of prognosis and may be better
detected using ECV% compared with late gadolinium
enhancement techniques (3). Further studies are
now required to assess whether CMR assessments of
myocardial fibrosis can improve the detection of LV
decompensation in aortic stenosis and optimize thetiming of aortic valve replacement (EVoLVeD [Early
Valve Replacement Guided by Biomarkers of LV
Decompensation in Asymptomatic Patients With Se-
vere AS]; NCT03094143).
Importantly, our data confirm the feasibility of
conducting international multicenter T1 mapping
studies and comparing ECV-based values acquired on
different scanners. The calculation of ECV% adjusts
myocardial T1 for blood pool T1 measurements made
on the same scanner. In principle, this should help
correct for between-scanner differences in measuring
T1 and enable comparison between ECV% values
(10,25). Here, we observed no difference in ECV%
values between patients imaged on Siemens or Phil-
lips platforms, at 1.5- or 3.0-T, or using different pulse
sequences (shortened vs. standard modified Look-
Locker inversion recovery). This observation should
now encourage similar multicenter T1 mapping
studies, investigating ECV% and iECV, in other car-
diovascular conditions.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Increased ECV%
measured by cardiovascular magnetic resonance is an objective
marker of left ventricular decompensation in patients with aortic
stenosis (AS) that predicts mortality.
TRANSLATIONAL OUTLOOK: Future research should explore
whether changes in ECV% can be used to guide the timing of
intervention for patients with AS.
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315STUDY LIMITATIONS. Native T1 has potential ad-
vantages as a marker of diffuse myocardial fibrosis,
being based upon a single measurement and avoiding
the need for gadolinium-based contrast administra-
tion. However, in this pragmatic multicenter setting,
native T1 was hampered by considerable variation in
values on different scanners. Recent studies have
demonstrated that this variability can, in part, be
addressed using phantom testing (31). This was not
addressed here (the phantoms were not industrially
manufactured at the time of recruitment) and re-
quires further investigation in patients with aortic
stenosis. Instead, we performed an exploratory
analysis correcting native T1 for normal T1 values
acquired in a sample of healthy volunteers imaged
with the same pulse sequence and scanner. Although
these adjusted native T1 values also demonstrated
associations with markers of LV decompensation,
they did not provide prognostic information. Pro-
spective studies with more robust methods for cor-
recting native T1 may be more successful. Subclinical
cardiac amyloid deposition was not excluded; this
would have required routine myocardial biopsies
or bone scintigraphy, which were not felt
warranted given the uncertain clinical importance of
this observation.
Although no effect of T1 mapping pulse sequence
on ECV% was demonstrated, this result cannot be
extrapolated to saturation recovery-based T1 map-
ping techniques, which were not examined and may
produce a lower ECV% value compared with inver-
sion recovery sequences (32). Finally, no data were
available regarding hospital admissions for heartfailure, although previous studies have demonstrated
a close association between this endpoint and all-
cause mortality (33).
CONCLUSIONS
ECV-based T1 mapping measurements are associated
with multiple measures of LV decompensation in
aortic stenosis. ECV% is a strong independent pre-
dictor of death in patients after aortic valve replace-
ment, with further work now required to determine
how these measures can be used to optimize the
timing of aortic valve intervention.
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